SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Pericay, Carles
- dc.contributor.author Montagut Viladot, Clara
- dc.contributor.author Reina, Juan José
- dc.contributor.author Melian, Marcos
- dc.contributor.author Alcaide, Julia
- dc.contributor.author Tarazona, Noelia
- dc.contributor.author Ruiz-Casado, Ana
- dc.contributor.author González-Flores, Encarnación
- dc.contributor.author Graña, Begoña
- dc.contributor.author Grávalos, Cristina
- dc.date.accessioned 2025-03-14T07:14:39Z
- dc.date.available 2025-03-14T07:14:39Z
- dc.date.issued 2024
- dc.description.abstract Colorectal cancer (CRC) has a 5-year overall survival rate of over 60%. The decrease in the rate of metastatic disease is due to screening programs and the population's awareness of healthy lifestyle. Similarly, advancements in surgical methods and the use of adjuvant chemotherapy have contributed to a decrease in the recurrence of resected disease. Before evaluating a patient's treatment, it is recommended to be discussed in a multidisciplinary tumor board. In stage II tumors, the pathologic characteristics of poor prognosis must be known (T4, number of lymph nodes analyzed less than 12, lymphovascular or perineural invasion, obstruction or perforation, poor histologic grade, presence of tumor budding) and it is mandatory to determine the MSI/MMR status for avoiding administering fluoropyridimidines in monotherapy to patients with MSI-H/dMMR tumors. In stage III tumors, the standard treatment consists of a combination of fluoropyrimidine (oral or intravenous) with oxaliplatin for 6 months although the administration of CAPOX can be considered for 3 months in low-risk tumors. Neoadjuvant treatment is not consolidated yet although immunotherapy is achieving very good preliminary results in MSI-H patients. The use of ctDNA to define the treatment and monitoring of resected tumors is only recommended within studies. These guidelines are intended to help decision-making to offer the best management of patients with non-metastatic colon cancer.
- dc.format.mimetype application/pdf
- dc.identifier.citation Pericay C, Montagut C, Reina JJ, Melian M, Alcaide J, Tarazona N, et al. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023). Clin Transl Oncol. 2024 Nov;26(11):2812-25. DOI: 10.1007/s12094-024-03559-5
- dc.identifier.doi http://dx.doi.org/10.1007/s12094-024-03559-5
- dc.identifier.issn 1699-048X
- dc.identifier.uri http://hdl.handle.net/10230/69938
- dc.language.iso eng
- dc.publisher Springer
- dc.relation.ispartof Clin Transl Oncol. 2024 Nov;26(11):2812-25
- dc.rights © The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Colorectal cancer
- dc.subject.keyword Guidelines
- dc.subject.keyword Localized disease
- dc.subject.keyword Systemic treatment
- dc.title SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023)
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion